Additional file 3 of Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Additional file 3: Figure S3. MTT proliferation assay in MM cell lines and peripheral blood mononuclear cells (PBMNCs) from healthy donors treated with CUDC-907. (a-h) each cell line was treated with DMSO, 10 nM CUDC-907, 25 nM CUDC-907, or 50 nM CUDC-907 for 72 h. the average was calculated for each experiment performed in quintuplicate (n = 5). (*p < 0.05, **p < 0.01, “ns” indicates no significant difference.) (i) PBMNCs were treated with DMSO, 2 μM ACY-1215 (ACY), 4 μM afuresertib (Afu), or a combination of ACY-1215 and afuresertib (comb) and 10 nM CUDC-907 (CUDC-907) for 72 h. the average was calculated for each experiment performed in quintuplicate (n = 5). (*p < 0.05, **p < 0.01, “ns” indicates no significant difference).